Striatal histone modifications in models of levodopa-induced dyskinesia

Journal of Neurochemistry

Volumn 106, Issue 1, 2008, Pages 486-494

  Nicholas, Anthony P ^a,b,h   Lubin, Farah D ^c   Hallett, Penelope J ^d   Vattem, Padmapriya ^a   Ravenscroft, Paula ^e   Bezard, Erwan ^f   Zhou, Shaobo ^e   Fox, Susan H ^g   Brotchie, Jonathan M ^g   Sweatt, J David ^c   Standaert, David G ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UMR 5287   (France)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h The University of Alabama at Birmingham   (United States)

Author keywords

Acetylation; Dyskinesia; Epigenetics; Histone deacetylase inhibitors; Macaque; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; HISTONE; HISTONE H3; HISTONE H4; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE 3;

ACETYLATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEACETYLATION; DEPHOSPHORYLATION; DYSKINESIA; FEMALE; MACACA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACETYLATION; ANIMALS; CHROMATIN; CHROMOSOME ABERRATIONS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HISTONES; LEVODOPA; MACACA MULATTA; MALE; METHYLATION; MICE; MICE, INBRED C57BL; PARKINSONIAN DISORDERS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SPECIES SPECIFICITY;

ANIMALIA; MURINAE; PRIMATES;

EID: 45249099791     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05417.x     Document Type: Article

References (50)

1. Ahlskog J. E. Muenter M. D. (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16, 448 458.
2. Alarcon J. M., Malleret G., Touzani K., Vronskaya S., Ishii S., Kandel E. R. Barco A. (2004) Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42, 947 959.
3. Andersson M., Hilbertson A. Cenci M. A. (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6, 461 474.
4. Aubert I., Guigoni C., Li Q., Dovero S., Bioulac B. H., Gross C. E., Crossman A. R., Blocha B. Bezard E. (2007) Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol. Psychiatry 61, 836 844.
5. Battaglioli E., Andres M. E., Rose D. W., Chenoweth J. G., Rosenfeld M. G., Anderson M. E. Mandel G. (2002) REST repression of neuronal genes requires components of the hSWI.SNF complex. J. Biol. Chem. 277, 41038 41045.
6. Bezard E., Brotchie J. M. Gross C. E. (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2, 577 588.
7. Bezard E., Gross C. E., Qin L., Gurevich V. V., Benovic J. L. Gurevich E. V. (2005) L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol. Dis. 18, 323 335.
8. Brami-Cherrier K., Valjent E., Herve D., Darragh J., Corvol J. C., Pages C., Arthur S. J., Girault J. A. Caboche J. (2005) Parsing molecular and behavioral effects of cocaine in mitogen- and stress-activated protein kinase-1-deficient mice. J. Neurosci. 25, 11444 11454.
9. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M. Kopin I. J. (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl Acad. Sci. USA 80, 4546 4550.
10. Butler R. Bates G. P. (2006) Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci. 7, 784 796.
11. Cantuti-Castelvetri I., Saka E., Keller-McGandy C. E. et al. (2007) Striatal thyrotropin releasing hormone is increased in response to chronic L-DOPA treatment in a rat model of Parkinson disease. Soc. Neurosci. Abstr. Program #254.11.2007, Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, Online.
12. Carta A. R., Tronci E., Pinna A. Morelli M. (2005) Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment. Eur. J. Neurosci. 21, 1196 1204.
13. Cenci M. A. (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci. 30, 236 243.
14. Chwang W. B., Arthur J. S., Schumacher A. Sweatt J. D. (2007) The nuclear kinase MSK1 regulates hippocampal chromatin remodeling in memory formation. J. Neurosci. 27, 12732 12742.
15. Cole D. G., Growdon J. H. DiFiglia M. (1993) Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra. Exp. Neurol. 120, 223 232.
16. Colvis C. M., Pollock J. D., Goodman R. H. et al. (2005) Epigenetic mechanisms and gene networks in the nervous system. J. Neurosci. 25, 10379 10389.
17. Cosgrove M. S. Wolberger C. (2005) How does the histone code work? Biochem. Cell Biol. 83, 468 476.
18. Doucet J. P., Nakabeppu Y., Bedard P. J. et al. (1996) Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur. J. Neurosci. 8, 365 381.
19. Eyal S., Yagen B., Sobol E., Altschuler Y., Shmuel M. Bialer M. (2004) The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45, 737 744.
20. Fahn S. (2000) The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 47 Suppl 1, S2 S9.
21. Freeman W. M., Patel K. M., Brucklacher R. M., Lull M. E., Erwin M., Morgan D., Roberts D. C. Vrana K. E. (2008) Persistent alterations in mesolimbic gene expression with abstinence from cocaine self-administration. Neuropsychopharmacology in press.
22. Gardian G., Yang L., Cleren C., Calingasan N. Y., Klivenyi P. Beal M. F. (2004) Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Med. 5, 235 241.
23. Hallett P. J., Dunah A. W., Ravenscroft P., Zhou S., Bezard E., Crossman A. R., Brotchie J. M. Standaert D. G. (2005) Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 48, 503 516.
24. Henry B., Duty S., Fox S. H., Crossman A. R. Brotchie J. M. (2003) Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp. Neurol. 183, 458 468.
25. Huang Y., Myers S. J. Dingledine R. (1999) Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. Nat. Neurosci. 2, 867 872.
26. Huang Y., Doherty J. J. Dingledine R. (2002) Altered histone acetylation at glutamate receptor 2 and brain-derived neurotrophic factor genes is an early event triggered by status epilepticus. J. Neurosci. 22, 8422 8428.
27. Jenner P., Rupniak N. M. J., Rose S., Kelly E., Kilpatrick G., Lees A. Marsden C. D. (1984) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in the common marmoset. Neurosci. Lett. 50, 85 90.
28. Jenuwein T. Allis C. D. (2001) Translating the histone code. Science 293, 1074 1080.
29. Konradi C., Westin J. E., Carta M., Eaton M. E., Kuter K., Dekundy A., Lundblad M. Cenci A. (2004) Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia. Neurobiol. Dis. 17, 219 236.
30. Kontopoulos E., Parvin J. D. Feany M. B. (2006) A-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15, 3012 3023.
31. Korzus E., Rosenfeld M. G. Mayford M. (2004) CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42, 961 972.
32. Kumar A., Choi K.-H., Renthal W. et al. (2005) Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron 48, 303 314.
33. Leng Y. Chuang D. M. (2006) Endogenous a-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci. 26, 7502 7512.
34. Levenson J. M. Sweatt J. D. (2005) Epigenetic mechanisms in memory formation. Nat. Rev. Neurosci. 6, 108 118.
35. Levenson J. M., O'Riordan K. J., Brown K. D., Trinh M. A., Molfese D. L. Sweatt J. D. (2004) Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 279, 40545 40559.
36. Levine A. A., Guan Z., Barco A., Xu S., Kandel E. R. Schwartz J. H. (2005) CREB-binding protein controls response to cocaine by acetylating histones at the fosB promoter in the mouse striatum. Proc. Natl Acad. Sci. USA 102, 19186 19191.
37. Lubin F. D. Sweatt J. D. (2007) The IkappaB kinase regulates chromatin structure during reconsolidation of conditioned fear memories. Neuron 55, 942 957.
38. Nadjar A., Brotchie J. M., Guigoni C. et al. (2006) Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. J. Neurosci. 26, 8653 8661.
39. Nicholas A. P. (2007) Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Mov. Disord. 22, 99 104.
40. Nielsen K. M. Soghomonian J. J. (2003) Dual effects of intermittent or continuous L-DOPA administration on gene expression in the globus pallidus and subthalamic nucleus of adult rats with a unilateral 6-OHDA lesion. Synapse 49, 246 260.
41. Pavón N., Martín A. B., Mendialdua A. Moratalla R. (2005) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry 59, 64 74.
42. Price P. A., Parkes J. D. Marsden C. D. (1978) Sodium valproate in the treatment of levodopa-induced dyskinesia. J. Neurol. Neurosurg. Psychiat. 41, 702 706.
43. Putignano E., Lonetti G., Cancedda L., Ratto G., Costa M., Maffei L. Pizzorusso T. (2007) Developmental downregulation of histone posttranslational modifications regulates visual cortical plasticity. Neuron 53, 747 759.
44. Santini E., Valjent E., Usiello A., Carta M., Borgkvist A., Girault J.-A., Herve D., Greengard P. Fisone G. (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J. Neurosci. 27, 6995 7005.
45. Standaert D. G. Young A. B. (2006) Treatment of central nervous system degenerative disorders, in Goodman and Gilman's Pharmacological Basis of Therapeutics, 10th Edn (Brunton L. L., ed pp. 527 546. McGraw-Hill, New York.
46. Tsankova N. M., Kumar A. Nestler E. J. (2004) Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures. J. Neurosci. 24, 5603 5610.
47. Tsankova N. M., Berton O., Renthal W., Kumar A., Neve R. L. Nestler E. J. (2006) Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 9, 519 525.
48. Tsankova N. M., Renthal W., Kumar A. Nestler E. J. (2007) Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8, 355 367.
49. Varga-Weisz P. D. Becker P. B. (1998) Chromatin-remodeling factors: machines that regulate? Curr. Opin. Cell Biol. 10, 346 353.
50. Wood M. A., Attner M. A., Oliveira A. M., Brindle P. K. Abel T. (2006) A transcription factor-binding domain of the coactivator CBP is essential for long-term memory and the expression of specific target genes. Learn. Mem. 13, 609 617.